Two Sigma Securities’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.68M Buy
+5,585
New +$1.68M 0.15% 143
2025
Q4
Sell
-1,740
Closed -$793K 1444
2025
Q3
$793K Buy
+1,740
New +$709K 0.12% 222
2025
Q2
Sell
-1,159
Closed -$313K 1469
2025
Q1
$313K Buy
1,159
+42
+4% +$10.8K 0.05% 567
2024
Q4
$263K Buy
+1,117
New +$294K 0.03% 745
2024
Q3
Sell
-54,142
Closed -$14.1M 2802
2024
Q2
$13.2M Buy
+54,142
New +$8.55M 0.16% 152
2023
Q3
Sell
-5,111
Closed -$975K 2893
2023
Q2
$971K Buy
5,111
+3,590
+236% +$712K 0.01% 990
2023
Q1
$305K Sell
1,521
-2,467
-62% -$519K 0.01% 1684
2022
Q4
$948K Buy
3,988
+881
+28% +$188K 0.03% 715
2022
Q3
$622K Sell
3,107
-8,183
-72% -$1.56M 0.02% 923
2022
Q2
$1.65M Buy
11,290
+3,782
+50% +$537K 0.06% 357
2022
Q1
$1.23M Buy
7,508
+5,383
+253% +$820K 0.04% 530
2021
Q4
$360K Buy
+2,125
New +$395K 0.02% 707
2021
Q3
Sell
-2,066
Closed -$350K 1519
2021
Q2
$350K Buy
+2,066
New +$303K 0.01% 880
2020
Q1
Sell
-2,404
Closed -$277K 1324
2019
Q4
$277K Buy
+2,404
New +$240K ﹤0.01% 1849
2018
Q2
Sell
-2,524
Closed -$250K 2615
2018
Q1
$301K Buy
+2,524
New +$325K ﹤0.01% 2001
2017
Q4
Sell
-2,039
Closed -$256K 1714
2017
Q3
$240K Sell
2,039
-1,413
-41% -$121K 0.02% 483
2017
Q2
$275K Buy
+3,452
New +$221K 0.05% 391

Other funds holding ALNY

Two Sigma Securities's ALNY Position: Q2 2026 in Review

Two Sigma Securities opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 5,585 shares worth $1.68M. The stake represents 0.15% of the portfolio and ranks #143 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in ALNY as recently as Q3 2025.

Two Sigma Securities first reported a position in ALNY in Q2 2017 and has held it in 17 quarters since. The position peaked at $13.2M in Q2 2024. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Two Sigma Securities held 5,585 shares of Alnylam Pharmaceuticals worth $1.68M as of Q2 2026.
  • Alnylam Pharmaceuticals was a new Two Sigma Securities position in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.15% of Two Sigma Securities's portfolio in Q2 2026, its #143 holding.
  • Two Sigma Securities first reported a position in Alnylam Pharmaceuticals in Q2 2017 and has held it in 17 quarters since.
  • Two Sigma Securities's Alnylam Pharmaceuticals position peaked at $13.2M in Q2 2024.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.